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• This is the ﬁrst post-marketing effectiveness study of Jitai tablets.
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Objective: The aim of the study was to compare the effectiveness of Jitai tablets (JTT) versus methadone in a
community drug treatment program.
Methods: A cohort study was conducted with 386 eligible subjects from 7 districts to 65 communities in
Shanghai. The subjects were placed into the JTT group (n = 206) or the methadone group (n = 180). The
data were collected at 8-, 26- and 52-week follow-ups.
Results: The retention rates of the methadone group at the 8-, 26-, and 52-week follow-ups were 97.78%,
91.67%, and 85.00%, respectively. The retention rates of the JTT group at these follow-ups were 90.78%,
83.50%, and 74.27%, respectively. A Chi-square test indicated a signiﬁcant difference, and the P values were
0.0037, 0.0161, and 0.0095 for each follow-up. The relapse rates for the JTT group were 3.88%, 6.31% and
11.17% for each follow-up, and those for the methadone group were 1.11%, 2.78%, and 7.78% for each
follow-up. The Chi-square test indicated no signiﬁcance, and the P values were 0.1128, 0.1005 and 0.2594.
A survival analysis indicated that the relapse survival curve had no signiﬁcant difference between the two
groups (log-rank test, P = 0.188).
Conclusion:Methadone and JTT combined with psychological intervention and social support provided effective
maintenance treatment and relapse prevention in a community drug treatment program. The retention rate in
the methadone group was higher, but the JTT group had the same relapse prevention as the methadone
group. JTT can be recommended to clinical doctors and drug addicts.© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Modern science has conﬁrmed that heroin addiction is a chronic
recurrent brain disease (Friedman & David, 2009; O'Brien & McLellan,ao).
td. Open access under CC BY-NC-ND license1996). Detoxiﬁcation alone has little beneﬁt and high rates of relapse.
Drug therapy combined with psychological rehabilitation and social in-
tervention measures is more effective in the treatment of heroin addic-
tion (Leshner, 1997; McLellan, Arndt, Metzger, et al., 1993; McLellan,
Lewis, O'Brien, et al., 2000; Woody, McLellan, Luborsky, et al., 1995).
With the implementation of a new anti-drug law on June 1, 2008,
China's existing drug treatment strategy is centered on community
drug treatment and mobilizes social services to help drug abusers re-
turn to society. The previous drug abuse policies based on required
labor and compulsory treatment have been incorporated into the
required isolation from society treatment model. As the number of.
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community-based drug-abuse recovery model has been a growing
trend in relapse prevention and successful detoxiﬁcation.
Jitai (JTT), which has been approved for the treatment of opiate
addiction by the Chinese State Food and Drug Administration (SFDA),
consists of 15 drugs, including Rhizoma corydalis, Radix salviae
miltiorrhizae, Radix angelicae sinensis, Ligusticum Chuanxiong, and
Flos Daturae. Animal experiments have shown that JTT provides a
positive effect equivalent to clonidine in detoxiﬁcation treatment
in morphine-addicted animals, with less harmful side effects (Lu,
Pan, Fang, et al., 1998). Clinical research ﬁndings have shown that
JTT can not only effectively control withdrawal symptoms in heroin
addicts but can also relieve protracted withdrawal symptoms after
a speciﬁc period of detoxiﬁcation and consolidate the detoxiﬁcation
curative effects. JTT has no dependence potential and no obvious ad-
verse effects (Dong, Wang, & Zhou, 2002; Xiong, Xiao, Li, et al., 2001;
Xu, Duan, Wang, et al., 2000). There have been no reports of a
post-marketing evaluation of JTT, such as effect evaluation and the
surveillance of drug-adverse reactions in large populations. This study
aims to explore the effectiveness of JTT combined with psychosocial
intervention in community drug treatment and uses methadone,
which is recognized worldwide for its effectiveness, as a control drug.2. Materials and methods
2.1. Design and interventions
A cohort studywith controls was designedwith the research groups
and intervention measures as follows.
Methadone group: We implemented methadone combined with
psychological intervention and social supports according to the
current community methadone maintenance treatment plan,
with a treatment period of 1 year, including baseline screening
and 8-, 26-, and 52-week follow-ups.
JTT group: We implemented JTT medication treatment combined
with psychological intervention and social supports, with a treat-
ment period of 1 year, including baseline screening and 8-, 26-,
and 52-week follow-ups. The psychological intervention consisted
of group psychological intervention and individual counseling.
The group psychology interventions consisted of 12 sessions over a
6-month period, with 1 session every two weeks, and were conducted
by social workers who had been trained by qualiﬁed specialist physi-
cians of the Shanghai mental health center. Each session had a theme,
referred to as a group discussion, on topics including the following;
role cognition; scene training; changing false understandings of family,
social and personal behavior; providing help; and emergencymeasures.
These sessions were scheduled for 1.5 h. Individual counseling was
conducted by setting up a psychological consultation telephone hotline
for actively seeking psychological support. The social support systems
included providing subsidies, recommending employment, vocational
training, medical fee reduction, conﬂict mediation, and family counsel-
ing, among others. Social workers are advocates for the participants
and help the relevant agencies address the needs of the program
participants.
Medication in treatment: JTT is dispensed in tablets of 0.4 g each.
It can be taken at home under the supervision of family members.
The participants receive a follow-up supply of the tablets according to
a community doctor's prescription, and the residual tablets are returned
at the next stage. The speciﬁc medication directions for taking JTT are
as follows: 3 tablets 2× per day for 8 weeks, 2 tablets 2× per day for
8–26 weeks, and then 1 tablet 2× per day for 16–52 weeks. Methadone
is an oral liquid, given ﬂexibly according to the individual situation by
doctors in doses of 15 ml to 120 ml everyday.2.2. Setting and participants
The research sites covered 65 streets in the following seven dis-
tricts of Shanghai: Yangpu, Pudong, Baoshan, Zhabei, Changning,
Putuo, and Hongkou. The participants were recruited from June
2010 to September 2010. All of the participants who were opiate de-
pendent (based on a clinical assessment), had not been prescribed ei-
ther study drug for the preceding month, and were requesting
maintenance treatment (for whom it was appropriate) were invited
to participate. To be included, the patients were required to meet all
of the following inclusion criteria: (1) between 18 and 65 years old;
(2) completed the acute detoxiﬁcation treatment; (3) meet the Diag-
nostic and Statistical Manual for Mental Disorders (4th ed., DSM-IV,
American Psychiatric Association, 1994) criteria for opiate depen-
dence; (4) patients (with a legal guardian) signed informed consent,
agreed to comply with medication regime and completed the rele-
vant information records for the duration of the study-based treat-
ment; and (5) accept the authority of police and anti-drug social
workers.
The patients were excluded if they had any of following exclusion
criteria: (1) the presence of comorbid severe mental illness (schizo-
phrenia, manic episodes, mental retardation); (2) a recent (in the
last 3 months) serious organic disease; (3) pregnancy or lactation;
or (4) ongoing medication treatment.
2.3. Measures
2.3.1. Treatment retention
Retention rate ¼ ðthe number of participants retained in treatment
=all of the participantsÞ  100%
Retained time was deﬁned as the length of maintenance therapy
from the initial prescription until lost to follow-up or the end of
research. The subjects were considered to be “not retained” in the
trial if they met one of the following standards: (1) canceled the
informed consent; (2) lost to follow-up; (3) poor compliance; (4) ad-
verse or serious adverse events occurred that could not be overcome;
(5) appearance of suicide ideation, self-injury or impulsive action
during the trial; (6) pregnancy; (7) violation of the experiment
design; or (8) other reasons that the researchers considered unfavor-
able to continue medication.
2.3.2. Illicit drug use
Illicit drug use is reﬂected as a relapse rate. Relapse was deﬁned as
participants who failed a urine toxicology test for illicit drugs or were
arrested by police and subject to compulsory isolation treatment
during the follow-up period. The frequency of urine sample testing
was a ﬂexible schedule based on the level of engagement and on
suspected or reported illicit drug use.
2.3.3. Safety indicators
The incidence rate and clinical manifestations of adverse events
and side effect were monitored.
2.4. Data processing and statistical analysis
We used the EpiData version 3.02 to set up the data. All analyses
were performed using SAS version 9.1. All of the statistical tests that
we reported were two sided, and statistical signiﬁcance was implied
at P ≤ 0.05. The continuous data, expressed as the means and stan-
dard deviations, were analyzed using a t-test, and the frequencies or
proportions of the categorical data were analyzed using Chi-square
test or Fisher's exact test to compare the baseline characteristics
and medical outcomes between the treatment projects. Kaplan–
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differences between the two groups.
2.5. Ethical approval
Ethical approval for this study was obtained from the Ethics
Committee of Shanghai Mental Health Center. Informed consent
was obtained from all participants.
3. Results
3.1. Baseline comparison
The data on the baseline characteristics of the participants of the
two groups are shown in Table 1. The overall statistical tests (t-test
or Chi-square tests) showed no signiﬁcant differences between the
groups in terms of gender, age, age at ﬁrst use of the drug, marriage,
education, and smoking or non-smoking (amount and time). There
were statistically signiﬁcant differences in terms of employment sta-
tus (in the last three years), previous medication, years of drug use
and number of previous detoxiﬁcations. The participants in the meth-
adone group were likely to have a higher proportion of previous med-
ication treatment, more years of drug use, and more previous
detoxiﬁcations. The participants in the JTT group were more likely
to be from a free-limited environment.
3.2. Treatment retention
The retention rates of the methadone group at the 8-, 26-, and
52-week follow-ups were 97.78%, 91.67%, and 85.00%, respectively;
the retention rates of the JTT group were 90.78%, 83.50%, andTable 1
Baseline comparison.
Characteristic Methadone
(N = 180)
n (%) or M(SD)
JTT
(N = 206)
n (%) or M(SD)
t or χ2 test P value
Gender
Male 146 (81.11%) 180 (87.38%) 2.87 0.090
Female 34 (18.89%) 26 (12.62%)
Age 42.25 (7.93) 40.98 (8.02) 1.56 0.1198
Age ﬁrst used drug 30.02 (7.88) 29.98 (8.33) 0.05 0.9628
Marriage
Unmarried 62 (34.44%) 88 (42.72%) 4.88 0.181
Married 62 (34.44%) 51 (24.76%)
Divorced 46 (25.56%) 56 (27.18%)
Others 10 (5.56%) 11 (5.34%)
Education
Primary 10 (5.56%) 5 (2.43%) 0.5917a
Junior high school 113 (62.78%) 137 (66.50%)
Senior high school 54 (30.00%) 59 (28.64%)
College degree
or above
3 (1.66%) 5 (2.43%)
Employment status
(in the last
three years)
Full-time job 30 (16.67%) 26 (12.62%) 46.88 b0.0001
Part-time job 18 (10.00%) 15 (7.28%)
Unemployed 114 (63.33%) 88 (42.72%)
Free-limited
environment
14 (7.78%) 76 (36.89%)
Others 4 (2.22%) 1 (0.49%)
Years of drug using 9.56 (4.33) 8.26 (4.83) 2.76 0.0060
Any previous
medication
100 (55.56%) 42 (20.39%) 51.09 b0.0001
Smoking history (year) 14.93 (9.69) 14.55 (10.14) 0.37 0.7133
Amount of smoke
(piece/day)
13.25 (8.56) 11.95 (8.27) 1.48 0.1404
Number of previous
detoxiﬁcation
3.48 (1.71) 2.93 (1.48) 3.32 0.0010
a Fisher's exact test.74.27%, respectively. Chi-square of independence analyses showed
statistical differences at the three follow-ups, and the P values were
0.0037, 0.0161, and 0.0095, respectively. The days retained averaged
334.7 ± 6.10 in the methadone group and 308.4 ± 7.87 in the JTT
group, and the statistical difference was achieved between the two
groups (t = 2.64, P = 0.0086).
The main reason for non-completion in both groups was being
arrested and jailed for illegal drug use, which occurred in 51.85% in
the methadone group and 39.62% in the JTT group.
3.3. Illicit drug use
3.3.1. Relapse rate
The relapse rates of the methadone group at the 8-, 26-, and
52-week follow-ups were 1.11%, 2.78%, and 7.78%, respectively, and
the relapse rates of the JTT group were 3.88%, 6.31%, and 11.17%,
respectively The Chi-square test showed no statistical differences at
any follow-up.
3.3.2. Survival analysis for relapse
A survival analysis of the 52-week follow-up demonstrated the
difference in relapse rates (Fig. 1). A log-rank test comparing JTT to
methadone indicated no statistically signiﬁcant difference (P = 0.188).
3.4. Side effects and adverse event
Those receiving JTT complained of side effects more than those
in the methadone group (7.28% vs. 0.56%, P = 0.001). The most
common side effects in the JTT group were xerostomia (3.88%),
somnolence (2.91%), gastrointestinal discomfort (1.94%), appetite
suppression (1.94%), blurred vision (1.94%), dizziness (0.97%), and
sweating (0.97%). These side effects were mild and primarily oc-
curred in the early stage of medication. Two participants in the
methadone group were injured in accidents, and one was hospital-
ized for another disease. One participant in the JTT group became
pregnant during the treatment.
4. Discussion
4.1. High retention rate and low relapse rate in community-based
drug treatment
We conducted a preliminary effectiveness evaluation of JTT versus
methadone in a community drug treatment program in terms ofLog rank test: P=0.188  
Fig. 1. Survival analysis showing relapse in treatment for JTT versus methadone.
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judging the maintenance status of the participants. In this study, the
12-month retention rates of the two groups were above 70%, and
the methadone group achieved 85%. Compared with domestic stud-
ies, the outcomes in our study were higher than those in other
study reports, which ranged from 30.1% to 63.7% in other provinces
that had no psychological intervention or social supports in drug
treatment programs (Chen, Xia, Chen, et al., 2009; Li, Tan, Sun,
et al., 2009; Liang, Liu, Zhong, et al., 2009; Yang, Duan, Xiang, et al.,
2011). The results were similar in Jiangsu province, which provided
psychological intervention and social support to the study subjects
(Xu, Chen, & Li, 2009).
Relapse rates are related to the deﬁnitions of relapse (Ciesla, 2010;
McKay, Alterman, Koppenhaver, et al., 2001; Saunders & Allsop,
1987). Although there is no consensual operational deﬁnition of the
term, the deﬁnitions of “relapse rate” generally range from a strict
standard to a loose standard as follows: a single drug use one time
after a period of abstinence; a positive drug test after a period of
abstinence; drug use with serious consequences after a period of
abstinence; and not maintaining withdrawal after a period of absti-
nence (three months or one-half of a year) (Fareed, Vayalapalli,
Stout, et al., 2011). High relapse rates have been generally observed
in other studies, and evidence suggests that the twelve-month relapse
rate following various classes of substance use ranges from 80 to 95%
(Brandon, Vidrine, & Litvin, 2007; Kirshenbaum, Olsen, & Bickel,
2009). The relapse rates in the JTT and methadone groups in this
study were below 15%, which is signiﬁcantly lower than the results
obtained in other national and international studies (Bao & Zhang,
2007; Brandon et al., 2007; Kirshenbaum et al., 2009; Lu, Gao, & Ni,
2010; Sun, Ye, & Qin, 2001), according to the strict deﬁnition of relapse
used in our study.
4.2. Analysis of advantages and disadvantages of JTT in community
drug treatment
Methadone is recommended by theWorld Health Organization for
use as a drug substitute in community drug treatment programs. The
efﬁcacy of methadone has been conﬁrmed by many studies during
the drug's nearly 50 years of development (Dole & Nyswander,
1965; Marsch, 1998; Mattick, Kimber, Breen, & Davoli, 2008). Some
research indicated that (Kayman, Goldstein, Deren, et al., 2006;
Schwartz, Kelly, O'Grady, et al., 2008) methadone may cause addic-
tion, and withdrawal from methadone is thought to be worse than
heroin withdrawal. In this study, we found that JTT displayed an
equivalent effect in relapse prevention and has advantages over
methadone. JTT is a Chinese compound formula tablet with no illegal
composition, and it does not cause addiction. Doctors can directly
prescribe JTT for patients, and it is convenient and helpful to protect
privacy and avoid social discrimination. JTT is a prospective medica-
tion for use in community drug treatment because of its low cost of
development and utilization and because we have valuable Chinese
herbal medicine resources. It was found that the side effect rate was
higher in the JTT group than in the methadone group, but these side
effects have been noted in patient information instruction booklets
about JTT. It is suggested that a clinical doctor prescribes a suitable
dose and that research and development scientists improve the com-
patibility of the medicines.
The limitations of the study must be acknowledged. This study
was nonrandomized, and selection bias therefore existed. Most par-
ticipants in the methadone group had taken methadone before enter-
ing the study, which may have produced adaptability and led to a
lower side effect rate than observed in the Jitai group. The prelimi-
nary evaluation of efﬁcacy and safety in the study was a comprehen-
sive result of JTT treatment versus methadone treatment combined
with psychological intervention and social support; the results were
not identiﬁed as the result of a single medication intervention.5. Conclusions
Methadone and JTT combined with psychological intervention
and social support showed effectiveness in promoting retention and
relapse prevention in community-based heroin addiction treatment.
Although the retention rate in the methadone group was higher, the
JTT group had the same results for relapse prevention as themethadone
group. JTT can be recommended to clinical doctors and drug addicts.
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